Aurora Cannabis Future Growth
Future criteria checks 1/6
Aurora Cannabis's earnings are forecast to decline at 52.1% per annum while its annual revenue is expected to grow at 13.7% per year. EPS is expected to decline by 51.1% per annum. Return on equity is forecast to be 8.4% in 3 years.
Key information
-52.1%
Earnings growth rate
-51.1%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 13.7% |
| Future return on equity | 8.4% |
| Analyst coverage | Good |
| Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
Aurora launches new cannabis products for adult and medical-use
Oct 17Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes
Oct 07Aurora Cannabis Q4 2022 Earnings Preview
Sep 19Aurora Cannabis: Don't Let Your Money Go Up In Smoke
Aug 25Why Did Aurora Cannabis Stock Crash In May; Can It Recover?
Jun 13Recent Developments Do Not Change Our Stance On Aurora Cannabis
May 13Aurora Cannabis: A Train Wreck Desperate For Help
May 05Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way
Feb 17Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?
Dec 17Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks
Oct 11Aurora Cannabis: Investors Should Have No Confidence In This Company
Sep 28Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity
Sep 16Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry
Jun 05Aurora Cannabis: Extreme Downside Case Averted
Feb 02Aurora Cannabis inks exclusive representative agreement with Great North Distributors
Jan 14How To Recoup Your Losses In Aurora Cannabis
Dec 24Aurora downgraded by BMO citing ‘out-of-line’ valuation
Dec 18Aurora to lay off 200 employees, idles substantial part of flagship Sky marijuana facility
Dec 16It's Not Just Aurora, Bearish On All Cannabis Stocks
Dec 08U.S. House gears up for historic vote on cannabis legalization
Dec 04Aurora Cannabis (ACB) Investor Presentation - Slideshow
Dec 02Aurora Cannabis inks supply deal for bulk dried flower with Cantek, shares down 6%
Nov 25Pot stocks rally as Trump administration proceeds with transition to Biden
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 410 | 19 | N/A | N/A | 2 |
| 3/31/2026 | 367 | 6 | 31 | 38 | 4 |
| 3/31/2025 | 320 | -8 | -15 | 20 | 6 |
| 3/31/2024 | 272 | -62 | -69 | -39 | 8 |
| 12/31/2023 | 276 | 411 | -99 | -83 | N/A |
| 9/30/2023 | 273 | 374 | -153 | -139 | N/A |
| 6/30/2023 | 258 | 331 | -149 | -139 | N/A |
| 3/31/2023 | 233 | -265 | -171 | -154 | N/A |
| 12/31/2022 | 212 | -1,748 | -181 | -157 | N/A |
| 9/30/2022 | 210 | -1,757 | -152 | -118 | N/A |
| 6/30/2022 | 221 | -1,718 | -142 | -110 | N/A |
| 3/31/2022 | 226 | -1,233 | -98 | -64 | N/A |
| 12/31/2021 | 231 | -381 | -122 | -82 | N/A |
| 9/30/2021 | 238 | -607 | -165 | -124 | N/A |
| 6/30/2021 | 245 | -692 | -264 | -211 | N/A |
| 3/31/2021 | 257 | -2,387 | -357 | -284 | N/A |
| 12/31/2020 | 275 | -2,359 | -430 | -285 | N/A |
| 9/30/2020 | 263 | -3,342 | -614 | -357 | N/A |
| 6/30/2020 | 269 | -3,231 | -691 | -342 | N/A |
| 3/31/2020 | 299 | -1,405 | -778 | -293 | N/A |
| 12/31/2019 | 291 | -1,430 | -787 | -289 | N/A |
| 9/30/2019 | 290 | -385 | -667 | -218 | N/A |
| 6/30/2019 | 246 | -294 | -606 | -192 | N/A |
| 3/31/2019 | 168 | -211 | -519 | -233 | N/A |
| 12/31/2018 | 119 | -72 | -439 | -206 | N/A |
| 9/30/2018 | 77 | 174 | -334 | -146 | N/A |
| 6/30/2018 | 55 | 72 | -219 | -82 | N/A |
| 3/31/2018 | 42 | -13 | -146 | -35 | N/A |
| 12/31/2017 | 31 | 7 | -91 | -16 | N/A |
| 9/30/2017 | 23 | -4 | N/A | -15 | N/A |
| 6/30/2017 | 18 | -13 | N/A | -13 | N/A |
| 3/31/2017 | 13 | -16 | N/A | -17 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -11 | N/A |
| 9/30/2016 | 5 | -10 | N/A | -9 | N/A |
| 6/30/2016 | 1 | -6 | N/A | -7 | N/A |
| 3/31/2016 | 0 | 0 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -3 | N/A |
| 6/30/2015 | N/A | -10 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACB's earnings are forecast to decline over the next 3 years (-52.1% per year).
Earnings vs Market: ACB's earnings are forecast to decline over the next 3 years (-52.1% per year).
High Growth Earnings: ACB's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ACB's revenue (13.7% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ACB's revenue (13.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACB's Return on Equity is forecast to be low in 3 years time (8.4%).